Saturday 17 October 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.98
1.36
−11.99%
Follow SLS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.50 | 10.25 | 16.60 | 18.29 | |
Current Ratio |
8.28 | 10.72 | 17.22 | 18.83 | |
Net Debt/EBITDA |
6.27 | 8.71 | 11.59 | 13.03 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.04 | 0.64 | 1.05 | 0.79 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.04 | 0.02 | 0.02 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.05) | (0.05) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.05) | (0.05) | (0.04) | |
Cash per Share |
0.41 | 0.66 | 0.62 | 0.73 | |
Shareholders Equity per Share |
0.42 | 0.65 | 0.62 | 0.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.42 | 0.65 | 0.62 | 0.73 | |
Free Cash Flow |
(7.07) | (4.92) | (8.85) | (7.59) | |
Working Capital |
43.13 | 68.19 | 104.71 | 134.94 | |
Net Current Asset Value |
43.13 | 67.74 | 104.40 | 134.78 | |
| Other line items | |||||
Average Payables |
3.43 | 3.22 | 3.69 | 3.21 | |
Average Assets |
39.03 | 48.89 | 74.57 | 88.84 | |
Average Common Equity |
30.76 | 40.17 | 67.59 | 81.90 |
Columns are period end dates